12,207 results on '"stevens–johnson syndrome"'
Search Results
2. NATIENS: Optimal Management and Mechanisms of SJS/TEN (NATIENS)
- Author
-
University of Ottawa, University of Toronto, and Elizabeth J Phillips, Principal Investigator
- Published
- 2024
3. Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study
- Published
- 2024
4. Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review.
- Author
-
Zhang, Xiaofang, Huang, Dihua, Lou, Dajun, Si, Xuwei, and Mao, Jiangfeng
- Subjects
- *
TYPE 1 diabetes , *ANTIBIOTICS , *INTRAVENOUS immunoglobulins , *DRUG side effects , *STEVENS-Johnson Syndrome , *TOXIC epidermal necrolysis , *CUTANEOUS manifestations of general diseases , *PANCREATIC beta cells , *INSULIN , *DIABETIC acidosis , *ITCHING , *HYPERGLYCEMIA , *INTRAVENOUS therapy , *SEIZURES (Medicine) , *DRUG eruptions , *ANTICONVULSANTS , *BLOOD sugar monitoring , *DISEASE risk factors , *DISEASE complications - Abstract
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin lesion triggered by hypersensitive drug reaction. They are characterized by extensive epidermal necrosis and skin exfoliation. Fulminant type 1 diabetes mellitus (FT1DM) is featured by a rapid-onset of hyperglycemia with ketoacidosis due to severely destroyed β-cell function. Fulminant type 1 diabetes mellitus as a sequela of SJS/TEN has rarely been reported. Case presentation: We present a 73-year-old female patient who developed SJS/TEN skin allergic reaction after taking carbamazepine and phenytoin for 35 days. Then, hyperglycemia and diabetic ketoacidosis occurred 20 days after discontinuation of antiepileptic drugs. A very low serum C-peptide level (8.79 pmol/l) and a near-normal glycosylated hemoglobin level met the diagnostic criteria for fulminant T1DM. Intravenous immunoglobulin (IVIG) and insulin were promptly administered, and the patient recovered finally. Conclusions: This rare case indicates that monitoring blood glucose is necessary in SJS/TEN drug reaction, and comprehensive therapy with rehydration, insulin, antibiotics, and IVIG may improve the prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating tumor necrosis factor-alpha inhibitors for dermatologic conditions.
- Author
-
Hennessee, Ian, Benedict, Kaitlin, Bahr, Nathan C., Lipner, Shari R., and Gold, Jeremy A.W.
- Published
- 2024
- Full Text
- View/download PDF
6. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study.
- Author
-
Chun-Xia He, Lan Guo, Tao Qu, and Hong-Zhong Jin
- Subjects
DRUG side effects ,KILLER cells ,TUMOR necrosis factors ,LYMPHOCYTE subsets ,IMMUNE checkpoint inhibitors ,TOXIC epidermal necrolysis - Abstract
Introduction: Immune-related epidermal necrolysis (irEN), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), represents a potentially lethal reaction to immune checkpoint inhibitors. An optimal treatment strategy remains undefined. This study evaluates the effectiveness and safety of combination therapy with corticosteroids and tumor necrosis factor inhibitors (TNFi) in treating irEN patients. Methods: In this single-center, prospective, observational study, patients with irEN received either corticosteroid monotherapy or a combination therapy of corticosteroids and TNFi (etanercept for SJS, infliximab for TEN). The primary endpoint was re-epithelization time, with secondary endpoints including corticosteroid exposure, major adverse event incidence, acute mortality rates, and biomarkers indicating disease activity and prognosis. The study was registered at the Chinese Clinical Trial Registry (ChiCTR2100051052). Results: Thirty-two patients were enrolled (21 SJS, 11 TEN); 14 received combination therapy and 18 received corticosteroid monotherapy. IrEN typically occurred after 1 cycle of ICI administration, with a median latency of 16 days. Despite higher SCORTEN scores in the combination group (3 vs. 2, p = 0.008), these patients experienced faster re-epithelization (14 vs. 21 days; p < 0.001), shorter corticosteroid treatment duration (22 vs. 32 days; p = 0.005), and lower prednisone cumulative dose (1177 mg vs. 1594 mg; p = 0.073). Major adverse event rates were similar between groups. Three deaths occurred due to lung infection or disseminated intravascular coagulation, with mortality rates for both groups lower than predicted. Potential risk factors for increased mortality included continuous reduction in lymphocyte subset counts (CD4
+ T cells, CD8+ T cells, natural killer cells) and consistent rises in inflammatory markers (serum ferritin, interleukin-6, TNF-α). Re-epithelization time negatively correlated with body mass index and positively correlated with epidermal detachment area and serum levels of interleukin-6 and TNF-α. Conclusions: Corticosteroids combined with TNFi markedly promote re-epithelization, reduce corticosteroid use, and decrease acute mortality in irEN patients without increasing major adverse events, offering a superior alternative to corticosteroid monotherapy. Inflammatory markers and lymphocyte subsets are valuable for assessing disease activity and prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. Toxic epidermal necrolysis caused by phenobarbital: a case report and literature review.
- Author
-
Jie Cheng, Hui Li, Yan Li, Xiao Li, Jianjun Wang, Xin Huang, and XueYan Cui
- Subjects
TOXIC epidermal necrolysis ,LITERATURE reviews ,PHENOBARBITAL ,STEVENS-Johnson Syndrome ,STATUS epilepticus ,PHYSICIANS - Abstract
Background: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare, life-threatening immunologic reactions. Previous relevant literature has provided limited information regarding this disease's genetic susceptibility and management principles. Objectives: This study aimed to describe a phenobarbital-induced TEN case report with HLA-B*15:02 and HLA-B*58:01 negative, CYP2C19*1/*2. In addition, we revised the existing literature on phenobarbital-induced SJS/TEN to explore its clinical characteristics. Methods: We describe a woman undergoing treatment with Phenobarbital for status epilepticus who developed classic cutaneous findings of TEN. A systematic search was conducted in the PubMed, Medline, WanFang, and CNKI databases from 1995 to 2023. The search terms used were "Stevens-Johnson Syndrome," "Toxic Epidermal Necrolysis," and "Phenobarbital." Results: We report a case of TEN resulting from phenobarbital; it tested negative for the HLA-B*15:02 and HLA-B*58:01 allele and CYP2C19*1/*2 intermediate metabolism. Supportive treatment with steroids and antihistamines resulted in complete resolution of the skin lesions and improvement in clinical symptoms after 14 days. Physicians and clinical pharmacists should be aware of these potential phenobarbital-related adverse events and closely monitor patients with first-time use of phenobarbital. Among 19 cases were identified in the literature, with 11 (57.9%) cases of SJS, 6 (31.6%) cases of TEN, and 2 (7.2%) cases of SJS-TEN/DRESS overlap. A total of 5 (26.3%) did not survive, of which 4 (21.1%) were under 12 years old and 1 (5.3%) was over 12 years old. Conclusion: Phenobarbital-induced SJS/TEN may still occur in patients who test negative for HLA-B*15:02 and HLA-B*58:01, CYP2C19*1/*2. Most cutaneous adverse events occur early in the course of Phenobarbital therapy and should be closely monitored early in the course of treatment. In addition, Phenobarbital should be used with caution in patients with a history of asthma and allergy to antipyretics and analgesics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Co-occurrence of oral pemphigus vulgaris and herpes simplex virus infection in a young patient with Crohn's disease: report of a rare case of oral lesions during anti-TFN alpha and immunomodulator therapy.
- Author
-
Lopes, Danielle Nobre, de Oliveira, Noêmia Pereira, de Campos Augusto, Karla Cristina, Milagres, Adrianna, Miguez, Ana Luiza, Junior, Arley Silva, Conde, Danielle Castex, Cunha, Karin Soares, Magalhães, Márcia Henriques, and Rozza-de-Menezes, Rafaela Elvira
- Subjects
- *
MUCOUS membrane diseases , *CROHN'S disease , *HERPES simplex , *INFLAMMATORY bowel diseases , *MEDICAL specialties & specialists , *ERYTHEMA multiforme , *STEVENS-Johnson Syndrome - Abstract
Background: Pemphigus vulgaris (PV) is a potentially life-threatening mucocutaneous autoimmune disease that affects desmoglein-1 and desmoglein-3, leading to intraepithelial vesiculobullous lesions. In the oral mucosa, PV lesions can mimic other diseases such as mucous membrane pemphigoid, other forms of pemphigus, recurrent aphthous stomatitis, erythema multiforme, Stevens-Johnson syndrome, and virus-induced ulcers like herpes simplex virus (HSV), making diagnosis challenging. The co-occurrence of PV with Crohn's disease is rare and predominantly seen in younger patients. The therapeutic mainstay for both PV and Crohn's disease usually involves systemic corticosteroids combined with immunosuppressants and immunobiological drugs. Literature indicates that the use of these drugs, particularly TNF-alpha inhibitors, for managing autoimmune diseases like Crohn's can potentially induce other autoimmune diseases known as autoimmune-like syndromes, which include episodes of lupus-like syndrome and inflammatory neuropathies. There are few cases in the literature reporting the development of PV in individuals with CD undergoing infliximab therapy. Case report. A young female with severe Crohn's disease, treated with the TNF-alpha inhibitor infliximab, developed friable pseudomembranous oral ulcerations. Histopathological and immunofluorescence analyses confirmed these as PV. The treatment included clobetasol propionate and low-level photobiomodulation, which resulted in partial improvement. The patient later experienced severe intestinal bleeding, requiring intravenous hydrocortisone therapy, which improved both her systemic condition and oral lesions. Weeks later, new ulcerations caused by herpes virus and candidiasis were identified, leading to treatment with oral acyclovir, a 21-day regimen of oral nystatin rinse, and photodynamic therapy, ultimately healing the oral infections. To manage her condition, the gastroenterologists included methotrexate (25 mg) in her regimen to reduce the immunogenicity of infliximab and minimize corticosteroid use, as the patient was in remission for Crohn's disease, and the oral PV lesions were under control. Conclusion: Young patients with Crohn's disease should be referred to an oral medicine specialist for comorbidity investigation, as oral PV and opportunistic infections can arise during immunosuppressive therapy. The use of TNF-alpha inhibitors in patients treated for inflammatory bowel disease, such as Crohn's, should be carefully evaluated for potential side effects, including oral PV. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. A toxikus epidermalis necrolysis szemészeti vonatkozásai.
- Author
-
Killik, Petra, Kostyál, Erika, Tóth, Gábor, Szentmáry, Nóra, Nagy, Zoltán Zsolt, and Maneschg, Otto Alexander
- Abstract
Copyright of Hungarian Medical Journal / Orvosi Hetilap is the property of Akademiai Kiado and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
10. Neutrophil‐driven and interleukin‐36γ‐associated ocular surface inflammation in chronic Stevens–Johnson syndrome.
- Author
-
Koduri, Madhuri Amulya, Pingali, Tejaswini, Prasad, Deeksha, Singh, Vijay, Singh, Swati, Shanbhag, Swapna S., Basu, Sayan, and Singh, Vivek
- Subjects
- *
LEUCOCYTE elastase , *LACRIMAL apparatus , *TOXIC epidermal necrolysis , *MATRIX metalloproteinases , *EYE inflammation , *SURGICAL margin - Abstract
Purpose: This study aims to elucidate the tear proteome and understand the underlying molecular mechanisms involved in the ocular complications following Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Methods: Mass spectrometry (MS) was performed to quantify the tear fluid proteins from chronic SJS/TEN patients (n = 22 eyes) and age‐ and gender‐matched controls (n = 22 eyes). The candidate proteins were validated using ELISA (n = 80 eyes) in tear samples and immunohistochemistry (IHC; n = 12) in eyelid margin specimens. These proteins were compared for significant differences based on age, gender, disease duration, and ocular severity. Results: A total of 1692 tear fluid proteins were identified, of which 470 were significantly differentially regulated in chronic SJS/TEN. The top 10 significantly upregulated proteins were neutrophil secretions including neutrophil elastase (p <.0001), defensin (p <.0001), and matrix metalloproteinase 8 (p <.0001). The presence of neutrophils was confirmed by the upregulation of IL‐8 (p <.001) in tears, a key cytokine known for recruiting neutrophils. Additionally, positive expression of myeloperoxidase was observed in the keratinized eyelid margins of SJS/TEN to validate the presence of neutrophils. Among 41 unique proteins identified by MS, IL‐36γ (p <.01) was expressed in three SJS/TEN patients and was confirmed in SJS/TEN tears and eyelid margins by ELISA and IHC, respectively. IL‐36γ was specifically expressed in the superficial layers of eyelid margin keratinized conjunctiva. The majority of the significantly downregulated proteins were lacrimal gland secretions such as lacritin (p <.0001) and opiorphin (p <.002). Neutrophil elastase (p <.02) was significantly elevated in patients with severe eyelid margin keratinization. Conclusion: Our observations indicate a clear correlation between eyelid margin keratinization and the expression of IL‐36γ, potentially mediated by neutrophils recruited via IL‐8. Future experimental studies are needed to test the role of therapies targeting IL‐8 and/or IL‐36γ in reducing eyelid margin keratinization and its associated ocular complications in SJS/TEN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
- Author
-
Yamamoto, Noboru, Kuboki, Yasutoshi, Harano, Kenichi, Koyama, Takafumi, Kondo, Shunsuke, Hagiwara, Akiko, Suzuki, Noriko, Fujikawa, Ei, Toyoizumi, Kiichiro, Mukai, Mayumi, and Doi, Toshihiko
- Subjects
THERAPEUTIC use of monoclonal antibodies ,FLOW cytometry ,STEVENS-Johnson Syndrome ,DRUG side effects ,PATIENT safety ,RESEARCH funding ,PROTEIN-tyrosine kinase inhibitors ,TERMINATION of treatment ,LOGISTIC regression analysis ,DESCRIPTIVE statistics ,DOSE-response relationship in biochemistry ,IMMUNE checkpoint inhibitors ,METASTASIS ,MONOCLONAL antibodies ,KAPLAN-Meier estimator ,COMBINED modality therapy ,DRUG efficacy ,TUMORS ,TIME ,EVALUATION ,PHARMACODYNAMICS - Abstract
Immune checkpoint inhibitors are the leading approaches in tumor immunotherapy. The aim of the study was to establish recommended phase 2 doses (RP2Ds) of intravenous cetrelimab, a checkpoint inhibitor, alone and with oral erdafitinib in Japanese patients with advanced solid tumors. This open-label, non-randomized, dose-escalation phase 1/1b study enrolled adults with advanced solid tumors who were ineligible for standard therapy. Study was conducted in two parts: phase 1a assessed cetrelimab at three dosing levels (80 mg every 2 weeks [Q2W], 240 mg Q2W, and 480 mg Q4W); phase 1b assessed cetrelimab+erdafitinib at two dosing levels (240 mg Q2W + 6 mg once daily [QD] and 240 mg Q2W + 8 mg QD). Primary endpoint was frequency and severity of dose-limiting toxicities (DLTs) of cetrelimab ± erdafitinib. In total 22 patients (phase 1a, n = 9; phase 1b, n = 13) were enrolled. Median duration of follow-up was 8.64 months in phase 1a and 2.33 months in phase 1b. In phase 1a, DLTs weren't reported while in phase 1b, 1 patient who received 240 mg cetrelimab + 6 mg erdafitinib reported Stevens-Johnson syndrome (grade 3, immune-related). Overall, 88.9% patients in phase 1a (grade ≥ 3: 44.4%) and 100.0% in phase 1b (grade ≥ 3: 53.8%) experienced ≥ 1 treatment-related adverse events (TEAEs); 33.3% in phase 1a and 38.5% in phase 1b reported serious TEAEs, of which 11.1% patients in phase 1a and 15.4% in phase 1b had TEAEs which led to treatment discontinuation. Cetrelimab alone and in combination with erdafitinib showed manageable safety in Japanese patients with advanced solid tumors. RP2Ds were determined as 480 mg cetrelimab Q4W for monotherapy, and cetrelimab 240 mg Q2W + erdafitinib 8 mg QD for combination therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Stevens–Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report.
- Author
-
Su, Chi-Sheng and Kao, Chi-Lan
- Subjects
- *
TOXIC epidermal necrolysis , *FAMOTIDINE , *QUETIAPINE , *DRUG side effects , *BODY surface area , *DRUG allergy - Abstract
Background: Stevens–Johnson syndrome-toxic epidermal necrolysis (SJS-TNE) overlap is a rare skin disorder characterized by erythema, blisters, extensive exfoliation, epidermal detachment, the involvement of multiple mucosae, and positive Nikolsky's sign. SJS-TEN has a high mortality rate. Our case involves a rare occurrence of drug-induced Stevens–Johnson syndrome-toxic epidermal necrolysis overlap with a delayed onset in the setting of quetiapine and famotidine therapy. Case presentation: An 82-year-old Taiwanese female was admitted to our hospital for decreased urine output, generalized edema, and multiple skin blisters and bedsores. With further spread of the lesions, multiple ruptured bullae with shallow erosions on the face, trunk, and limbs and mucosal involvement affected 20% of the total body surface area. Nikolsky's sign was positive. A diagnosis of Steven–Johnson syndrome was highly suspected. One month prior, she had started famotidine and quetiapine. Intravenous methylprednisolone treatment was initiated, which ameliorated the skin lesions after 3 days. However, new lesions developed after only 1 day of methylprednisolone tapering. The patient died 12 days after admission. Conclusion: Stevens–Johnson syndrome-toxic epidermal necrolysis is a rare skin disorder. Although it is mainly acute and has a high mortality rate, delayed onset can still occur. Quetiapine and famotidine are generally safe and effective for treating geriatric and gastrointestinal problems, but rare drug hypersensitivity reactions can lead to debilitating consequences. Therefore, increased clinical awareness and the initiation of supportive care are imperative. Optimal management guidelines are still lacking, and confirmation of developed guidelines through randomized controlled trials is needed. Collaboration for better management strategies is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.
- Author
-
Jia Zhou, Chuan-Peng Wang, Jun Li, Han-Lin Zhang, and Chun-Xia He
- Subjects
TOXIC epidermal necrolysis ,IMMUNE checkpoint inhibitors ,STEVENS-Johnson Syndrome ,NON-small-cell lung carcinoma ,BODY surface area ,DRUG side effects ,INTRAVENOUS immunoglobulins - Abstract
Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare yet life-threatening adverse events associated with immune checkpoint inhibitors (ICIs). This systematic review synthesizes the current literature to elucidate the clinical characteristics and outcomes of patients with ICI-related SJS/TEN. Methods: We conducted a thorough search across databases including Embase, Web of Science, Cochrane, MEDLINE, Scopus, and PubMed. Selection criteria focused on reports of SJS/TEN among cancer patients treated with ICIs, analyzing clinical manifestations, therapeutic interventions, and outcomes. Results: Our analysis included 47 articles involving 50 patients with ICI-related SJS/TEN. The cohort had a mean age of 63 years, with a slight male predominance (54%). Most patients had melanoma or non-small cell lung cancer. SJS/TEN typically occurred early, with a median onset of 23 days postICI initiation. Treatment primarily involved systemic corticosteroids and intravenous immunoglobulins. The overall mortality rate was 20%, higher for TEN at 32%, with infections and tumor progression as leading causes. Median time from onset to death was 28 days. Survivors experienced a median reepithelization time of 30 days, positively correlated with the extent of epidermal detachment (rs = 0.639, p = 0.009). Deceased patients exhibited a significantly higher proportion of TEN (90% vs. 48%, p = 0.029) and a larger epidermal detachment area (90% vs. 30% of the body surface area [BSA], p = 0.005) compared to survivors. The combination therapy group showed a higher proportion of TEN compared to corticosteroid monotherapy or noncorticosteroid therapy groups (72% vs. 29% and 50%, p = 0.01), with no significant differences in mortality or re-epithelization time. Dual ICI therapy resulted in a higher TEN rate than single therapy (100% vs. 50%, p = 0.028). Among single ICI therapies, the sintilimab-treated group trended towards a higher TEN rate (75% vs. 40-50%, p = 0.417), a larger detachment area (90% vs. 30-48% of BSA, p = 0.172), and a longer re-epithelization time (44 vs. 14-28 days, p = 0.036) compared to other ICI groups, while mortality rates remained similar. Conclusion: ICI-related SJS/TEN substantially impacts patient outcomes. Prospective clinical trials are critically needed to further clarify the pathogenesis and optimize therapeutic regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Characterizing drug‐induced epidermal necrolysis in a pediatric cohort.
- Author
-
Brown, Ariel B., Park, Andrew J., Agim, Nnenna G., and Gordon, Katherine A.
- Subjects
- *
TOXIC epidermal necrolysis , *DRUG side effects , *CHILD patients , *ANTICONVULSANTS - Abstract
This study aims to characterize the timeline and clinical features of onset, progression, and management of drug‐induced epidermal necrolysis in pediatric patients. Sixteen pediatric patients were retrospectively identified and selected if under age 18 years at admission with one identified culprit drug exposure. Culprit drugs were antiepileptics (12/16, 75%) and antibiotics (4/16, 25%). Notably, anti‐epileptic drugs (AED) had delayed onset and reported dose escalations that precipitated symptom onset; thus, patients prescribed AED with or without planned dose escalations should be monitored for prodromal symptoms longer than the typical onset window. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Toxic epidermal necrolysis‐like cutaneous toxicity following chimeric antigen receptor T‐cell therapy in recurrent large B‐cell lymphoma.
- Author
-
Bhullar, Puneet K., Motaparthi, Kiran, Zieman, Daniel P., Johnson, Cassandra, Gurnani, Pooja, and Sokumbi, Olayemi
- Subjects
- *
DERMATOTOXICOLOGY , *CHIMERIC antigen receptors , *DIFFUSE large B-cell lymphomas , *B cells , *ANTIGEN receptors , *FEVER , *T cells , *TOXIC epidermal necrolysis , *B cell receptors - Abstract
Chimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable success in treating various B‐cell malignancies, redirecting T‐cell cytotoxicity toward cancer cells. Despite its efficacy, CAR‐T therapy is associated with potential risks, including cytokine release syndrome (CRS) and cytopenia. We present a case of a 69‐year‐old man with diffuse large B‐cell lymphoma treated with axicabtagene‐ciloleucel CAR‐T therapy, who developed a rare and severe cutaneous toxicity resembling toxic epidermal necrolysis (TEN). The patient exhibited persistent fevers, CRS, and subsequent development of a widespread erythematous macular eruption, progressing to vesiculation with bullae. Notably, allopurinol‐induced TEN was considered with the patient's recent exposure to allopurinol, although the onset and minimal mucosal involvement did not align with typical presentations of allopurinol‐induced cases. The cutaneous reaction, distinct from typical SJS/TEN, showed minimal mucosal involvement and coincided with the cytokine release storm, differing from allopurinol‐induced TEN. Despite the absence of guidelines, the patient was managed with systemic steroids, achieving significant improvement. This case expands the spectrum of CAR‐T therapy‐related cutaneous toxicities, highlighting the need for early recognition of histopathology and tailored management by dermatologists. Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
- Author
-
Pach, Jolanta, Valido, Kailyn, Belzer, Annika, and Leventhal, Jonathan S.
- Subjects
- *
ADRENOCORTICAL hormones , *SKIN diseases , *STEVENS-Johnson Syndrome , *VITILIGO , *IMMUNE checkpoint inhibitors , *ITCHING , *DRUG efficacy , *ECZEMA - Abstract
Cutaneous immune-related adverse events encompass a spectrum of dermatological manifestations, including lichenoid reactions, psoriasiform eruptions, eczematous dermatitis, immunobullous disorders, granulomatous reactions, pruritus, vitiligo, and severe cutaneous adverse reactions such as Stevens–Johnson syndrome. The conventional approach to treating high-grade or refractory cutaneous immune-related adverse events has involved high-dose systemic corticosteroids. However, their use is limited owing to the potential disruption of antitumor responses and associated complications. To address this, corticosteroid-sparing targeted immunomodulators have been explored as therapeutic alternatives. Biologic agents, commonly employed for non-cutaneous immune-related adverse events such as colitis, are increasingly recognized for their efficacy in treating various patterns of cutaneous immune-related adverse events, including psoriasiform, immunobullous, and Stevens–Johnson syndrome-like reactions. This review consolidates findings from the English-language literature, highlighting the use of biologic agents in managing diverse cutaneous immune-related adverse event patterns, also encompassing maculopapular, eczematous, and lichenoid eruptions, pruritus, and transient acantholytic dermatosis (Grover disease). Despite the established efficacy of these agents, further research is necessary to explore their long-term effects on antitumor responses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Diagnostic discordance of Stevens-Johnson syndrome and toxic epidermal necrolysis between dermatologists and primary inpatient teams: a single-institution retrospective chart review.
- Author
-
Vaccarello, Annalise, Ouyang, Kelsey, Treichel, Alison M., Kumar, Yash, and Sharma, Timmie R.
- Published
- 2024
- Full Text
- View/download PDF
18. Generalized Fixed Drug Eruptions Require Urgent Care: A Case Series.
- Author
-
Shirer Barker, Catherine, Elston, Dirk M., and Lee, Katherine
- Subjects
DRUG eruptions ,INTENSIVE care units ,STEVENS-Johnson Syndrome ,OUTPATIENT medical care ,DEATH rate - Abstract
A generalized fixed drug eruption (FDE) is an uncommon but potentially dangerous reaction to medication. In this case series, we present 1 patient with a generalized FDE and 2 patients with generalized bullous FDE that resolved with cyclosporine, though 1 patient required close monitoring in the intensive care unit. Immediate acceleration of care upon development and recognition of generalized bullous FDE is essential, as the mortality rate is similar to Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review
- Author
-
Xiaofang Zhang, Dihua Huang, Dajun Lou, Xuwei Si, and Jiangfeng Mao
- Subjects
Severe cutaneous adverse reactions (SCARs) ,Stevens-Johnson syndrome ,Toxic epidermal necrolysis ,Antiepileptic drugs ,Fulminant type 1 diabetes mellitus ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin lesion triggered by hypersensitive drug reaction. They are characterized by extensive epidermal necrosis and skin exfoliation. Fulminant type 1 diabetes mellitus (FT1DM) is featured by a rapid-onset of hyperglycemia with ketoacidosis due to severely destroyed β-cell function. Fulminant type 1 diabetes mellitus as a sequela of SJS/TEN has rarely been reported. Case presentation We present a 73-year-old female patient who developed SJS/TEN skin allergic reaction after taking carbamazepine and phenytoin for 35 days. Then, hyperglycemia and diabetic ketoacidosis occurred 20 days after discontinuation of antiepileptic drugs. A very low serum C-peptide level (8.79 pmol/l) and a near-normal glycosylated hemoglobin level met the diagnostic criteria for fulminant T1DM. Intravenous immunoglobulin (IVIG) and insulin were promptly administered, and the patient recovered finally. Conclusions This rare case indicates that monitoring blood glucose is necessary in SJS/TEN drug reaction, and comprehensive therapy with rehydration, insulin, antibiotics, and IVIG may improve the prognosis.
- Published
- 2024
- Full Text
- View/download PDF
20. A nationwide study of Stevens–Johnson syndrome and toxic epidermal necrolysis in hospitalized pregnant women in the United States, 2009–2020Capsule Summary
- Author
-
Paul Wasuwanich, BSc, Robert S. Egerman, MD, Tony S. Wen, MD, and Kiran Motaparthi, MD
- Subjects
autoimmune diseases ,communicable diseases ,epidemiology ,public health ,Stevens-Johnson syndrome ,toxic epidermal necrosis ,Dermatology ,RL1-803 - Abstract
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rarely described in the pregnant population, and knowledge of their impact on the mother/fetus is limited. Objective: To describe SJS/TEN in pregnant women and to investigate the risk factors for developing SJS/TEN in pregnancy. Methods: We utilized hospitalization data from the 2009–2020 National Inpatient Sample. Pregnancy hospitalizations and SJS/TEN involvement were identified by ICD-9/10 codes and analyzed by chi-square and logistic regression. Results: We identified 650 pregnancies complicated by SJS/TEN requiring hospitalization. The median age was 28 years, and most were non-Hispanic White (55.2%). There were ≤10 cases associated with mortality. Most SJS/TEN cases (73.9%) occurred during the third trimester. HIV infection (OR = 9.49; P = .030), herpes simplex virus infection (OR = 2.49; P = .021), genitourinary tract infections (OR = 3.80; P
- Published
- 2024
- Full Text
- View/download PDF
21. Reactive Infectious Mucocutaneous Eruption with Extensive Cutaneous Involvement
- Author
-
Zeynoire Anderson, Audrey Fotouhi, Starling Tolliver, and Darius Mehregan
- Subjects
child ,drug eruption ,enterovirus ,mucositis ,stevens–johnson syndrome ,Dermatology ,RL1-803 - Abstract
Recently, there has been discussion to reclassify pediatric Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) as drug-induced epidermal necrolysis (DEN), separating it from infectious etiologies and redefining pediatric mucocutaneous eruptions as either reactive infectious mucocutaneous eruption (RIME) or DEN. In this report, we describe a previously healthy 4-year-old girl with rapidly progressive mucocutaneous blistering involving four mucosal membranes and 37.5% of total body surface area (BSA) following a prodromal rhinovirus and enterovirus infection. The symptoms occurred in the absence of an inciting medication and improved with only supportive care. This case illustrates a rare occurrence of RIME with TEN-like BSA involvement, prompting a review of the literature exploring the relationship between BSA involvement in RIME and its influence on patient outcomes. Findings support the proposed reclassification of SJS/TEN as DEN and postinfectious mucocutaneous eruptions as RIME.
- Published
- 2024
- Full Text
- View/download PDF
22. Stevens–Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report
- Author
-
Chi-Sheng Su and Chi-Lan Kao
- Subjects
Stevens–Johnson syndrome ,Quetiapine fumarate ,Antipsychotic agents ,Famotidine ,Histamine H2 antagonists ,Case reports ,Medicine - Abstract
Abstract Background Stevens–Johnson syndrome-toxic epidermal necrolysis (SJS-TNE) overlap is a rare skin disorder characterized by erythema, blisters, extensive exfoliation, epidermal detachment, the involvement of multiple mucosae, and positive Nikolsky’s sign. SJS-TEN has a high mortality rate. Our case involves a rare occurrence of drug-induced Stevens–Johnson syndrome-toxic epidermal necrolysis overlap with a delayed onset in the setting of quetiapine and famotidine therapy. Case presentation An 82-year-old Taiwanese female was admitted to our hospital for decreased urine output, generalized edema, and multiple skin blisters and bedsores. With further spread of the lesions, multiple ruptured bullae with shallow erosions on the face, trunk, and limbs and mucosal involvement affected 20% of the total body surface area. Nikolsky’s sign was positive. A diagnosis of Steven–Johnson syndrome was highly suspected. One month prior, she had started famotidine and quetiapine. Intravenous methylprednisolone treatment was initiated, which ameliorated the skin lesions after 3 days. However, new lesions developed after only 1 day of methylprednisolone tapering. The patient died 12 days after admission. Conclusion Stevens–Johnson syndrome-toxic epidermal necrolysis is a rare skin disorder. Although it is mainly acute and has a high mortality rate, delayed onset can still occur. Quetiapine and famotidine are generally safe and effective for treating geriatric and gastrointestinal problems, but rare drug hypersensitivity reactions can lead to debilitating consequences. Therefore, increased clinical awareness and the initiation of supportive care are imperative. Optimal management guidelines are still lacking, and confirmation of developed guidelines through randomized controlled trials is needed. Collaboration for better management strategies is warranted.
- Published
- 2024
- Full Text
- View/download PDF
23. Among the mimickers of Stevens-Johnson syndrome: A case of anasarca-induced skin desquamation
- Author
-
Rachel Manci, MD, William Guo, MD, Matthew Chen, BS, Jeremy Hugh, MD, and Katherine Siamas, MD
- Subjects
anasarca ,case report ,skin desquamation ,Stevens-Johnson syndrome ,toxic epidermal necrolysis ,Dermatology ,RL1-803 - Published
- 2024
- Full Text
- View/download PDF
24. Cultural and Ethnic Perspectives in Psychopharmacology
- Author
-
Lin, Keh-Ming, Braakman, Mario, Shimoda, Kazutaka, Yasui-Furukori, Norio, Kanba, Shigenobu, Section editor, El-Mallakh, Rif S., Section editor, Zohar, Joseph, Section editor, Krystal, Andrew D., Section editor, Tasman, Allan, editor, Riba, Michelle B., editor, Alarcón, Renato D., editor, Alfonso, César A., editor, Kanba, Shigenobu, editor, Lecic-Tosevski, Dusica, editor, Ndetei, David M., editor, Ng, Chee H., editor, and Schulze, Thomas G., editor
- Published
- 2024
- Full Text
- View/download PDF
25. Penicillin and Beta-Lactam Drug Allergy
- Author
-
Zhao, Wei, Zuelzer, Wilhelm A., editor, and Metikala, Sreenivasulu, editor
- Published
- 2024
- Full Text
- View/download PDF
26. Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis (TEN)
- Author
-
Peng Zhang, Investigator
- Published
- 2023
27. Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. (CELOPHIN)
- Author
-
Effice Servicios Para la Investigacion S.L.
- Published
- 2023
28. Daily compared with alternate-day levamisole in pediatric nephrotic syndrome: an open-label randomized controlled study.
- Author
-
Banerjee, Sushmita, Sengupta, Jayati, Sinha, Rajiv, Chatterjee, Suparna, Sarkar, Subhankar, Akhtar, Shakil, Saha, Rana, and Pahari, Amitava
- Subjects
- *
PATIENT compliance , *LEUKOCYTE count , *DRUG side effects , *STEVENS-Johnson Syndrome , *STATISTICAL sampling , *DRUG therapy , *EXANTHEMA , *HEMOGLOBINS , *DISEASE remission , *PREDNISOLONE , *RANDOMIZED controlled trials , *CHI-squared test , *MANN Whitney U Test , *DESCRIPTIVE statistics , *FEVER , *NEPHROTIC syndrome , *LOG-rank test , *KAPLAN-Meier estimator , *LONGITUDINAL method , *CHICKENPOX , *DRUG efficacy , *DISEASE relapse , *DRUGS , *DATA analysis software , *COMPARATIVE studies , *IMIDAZOLES , *DISEASE incidence , *NEUTROPENIA , *DISEASE risk factors , *CHILDREN - Abstract
Background: Levamisole is less expensive and has a better toxicity profile compared to other steroid sparing agents used in nephrotic syndrome. It has a plasma half-life of 2.0 to 5.6 hours, but is conventionally administered on alternate days. We aimed to assess whether daily levamisole is safe and more effective than standard alternate-day therapy in maintaining remission in children with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS). Methods: An open-label randomized controlled trial was conducted in children with FR/SDNS. Group A received daily while Group B received alternate-day levamisole (2–3 mg/kg/dose) for 12 months. Prednisolone was tapered off by 3 months. Patients were monitored for relapses, further steroid requirement, and adverse effects. Results: A total of 190 children with FR/SDNS (94 in Group A and 96 in Group B) were analyzed. Sustained remission for 12 months was observed in 36% of Group A and 27% of Group B patients (p = 0.18). Numbers completing 12 months in the study were 67% in Group A and 56% in Group B (p = 0.13). Time to first relapse, persistent FR/SDNS, and withdrawal due to poor compliance were statistically similar in both groups, while relapse rate and cumulative steroid dosage were significantly lower in Group A compared to Group B (p = 0.03 and p = 0.02, respectively). The incidence of adverse effects was comparable in both groups, with reversible leucopenia and hepatic transaminitis being the commonest. Conclusions: Daily levamisole therapy was not superior to alternate-day therapy in maintaining sustained remission over 12 months. Nevertheless, relapse rate and cumulative steroid dosage were significantly lower without increased adverse effects. A higher resolution version of the Graphical abstract is available as Supplementary information [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. The role of Mycoplasma pneumoniae in dermatological diseases
- Author
-
Zofia Podraza, Aneta Durmaj, Małgorzata Papierzewska, Joanna Czuwara, and Lidia Rudnicka
- Subjects
mycoplasma pneumoniae ,urticaria ,erythema multiforme ,stevens-johnson syndrome ,mycoplasma-induced rash with mucositis ,erythema nodosum ,leukocytoclastic vasculitis ,iga vasculitis ,subcorneal pustular dermatosis ,gianotti-crosti syndrome ,sweet syndrome ,Medicine ,Dermatology ,RL1-803 - Abstract
Mycoplasma pneumoniae is an atypical bacterium causing respiratory tract infections mainly in the pediatric population. As a superantigen, it dysregulates the immune system and promotes immunological reactions. Dermatological symptoms occur in approximately one-fourth of the patients infected with this bacterium. This review describes skin diseases occurring during Mycoplasma pneumoniae infection. Differences in the course of these diseases compared to their presentation associated with other etiological factors, are also discussed. Among the cutaneous manifestations of Mycoplasma pneumoniae infection, unspecific rashes and urticaria are the most common. This bacterium is also a frequent cause of erythema multiforme, Stevens-Johnson syndrome, Mycoplasma-induced rash and mucositis, and erythema nodosum. Less frequently toxic epidermal necrolysis, leukocytoclastic vasculitis, IgA vasculitis, subcorneal pustular dermatosis, Gianotti-Crosti syndrome, and Sweet syndrome are described. Familiarity with Mycoplasma-induced entities is important and can be useful in dermatological practice in determining the etiology and implementing appropriate treatment.
- Published
- 2024
- Full Text
- View/download PDF
30. Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients
- Author
-
Funda Erduran, Esra Adışen, Selma Emre, Yıldız Hayran, Emel Bülbül Başkan, Serkan Yazıcı, Aslı Bilgiç, Erkan Alpsoy, Sibel Doğan Günaydın, Leyla Elmas, Melih Akyol, RukiyeYasak Güner, Deniz Aksu Arıca, Yağmur Aypek, Tülin Ergun, Dilan Karavelioğlu, Ayça Cordan Yazıcı, Kübra Aydoğan, Dilek Bayramgürler, Rebiay Kıran, Hilal Kaya Erdoğan, Ersoy Acer, and Akın Aktaş
- Subjects
Stevens-Johnson syndrome ,Toxic epidermal necrolysis ,SCORTEN ,Plasmapheresis ,Mortality ,Survival ,Dermatology ,RL1-803 - Abstract
Abstract Introduction Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening acute mucocutaneous disorders usually triggered by drugs. In this study, we aimed to evaluate the factors affecting mortality in patients with SJS-TEN. Methods Our study is a retrospective cohort study, analyzing data collected from a total of 12 tertiary care centers between April 2012 and April 2022. Results The study included 59 males and 107 females, a total of 166 patients, with an average age of 50.91 ± 21.25 years. Disease classification was TEN in 50% of cases, SJS in 33.1%, and SJS-TEN overlap in 16.9%. The average SCORTEN within the first 24 h was 2.44 ± 1.42. Supportive care was provided to 99.4% of patients. The most commonly used systemic immunomodulatory treatments were systemic steroids (84.3%), IVIG (intravenous immunoglobulin) (49.3%), and cyclosporine (38.6%). Plasmapheresis was administered to five patients. While 66.3% of patients were discharged, 24.1% resulted in exitus. Our comparative analysis of survivors and deceased patients found no effect of systemic steroids, IVIG, and cyclosporine treatments on mortality. Univariate analysis revealed that the SCORTEN scores on days 1 and 3 as well as the rates of detachment at the onset and during follow-up were significantly higher in deceased patients compared to survivors. The rates of fever, positive blood cultures, and systemic antibiotic use were higher in deceased patients compared to survivors. The presence of comorbidities, diabetes, and malignancy were significantly more common in deceased patients. Multivariate regression analysis indicated that over SCORTEN 2, the mortality risk exponentially rose with each SCORTEN increment, culminating in an 84-fold increase in mortality at SCORTEN 5–6 (odds ratio [95% confidence interval]: 13.902–507.537, p
- Published
- 2024
- Full Text
- View/download PDF
31. The outcomes of corneal sight rehabilitating surgery in Stevens-Johnson syndrome: case series
- Author
-
Rongmei Peng, Miaomiao Chi, Gege Xiao, Hongqiang Qu, Zhan Shen, Yinghan Zhao, and Jing Hong
- Subjects
Stevens-Johnson syndrome ,Keratoplasty ,Keratolimbal allograft ,Toxic epidermal necrolysis ,Ocular SJS ,Ophthalmology ,RE1-994 - Abstract
Abstract Purpose To summarize the outcomes of corneal sight rehabilitating surgery in Stevens-Johnson syndrome (SJS). Methods This is a retrospective analysis of a consecutive case series. Twenty-four eyes of 18 SJS patients were included in this study. The ocular parameters, surgical procedures, postoperative complications, and additional treatments of the cases were reviewed. Results A total of 29 corneal sight rehabilitating surgeries, which consists of 9 keratoplasties, 8 Keratolimbal allograft (KLAL) and 12 combined surgeries (keratoplasty and KLAL simultaneously) were performed on the 24 eyes. All patients were treated with glucocorticoid eyedrops and tacrolimus eyedrops for anti-rejection treatment without combining systemic immunosuppression, except two patients who were prescribed prednisone tablets for the management of systemic conditions. The mean follow-up period was 50.6 ± 28.1 months. The optimal visual acuity (VA) (0.74 ± 0.60 logarithm of the minimum angle of resolution [logMAR]) and endpoint VA (1.06 ± 0.82 logMAR) were both significantly better than the preoperative VA (1.96 ± 0.43 logMAR) (95% CI, p = 0.000). 57.1% patients (8/14) were no longer in the low vision spectrum, and 88.9% patients (8/9) were no longer blind. The mean epithelialization time was 7.1 ± 7.6 weeks. The success rate was 86.7%. Additional treatments for improving epithelialization included administration of serum eyedrops (n = 10), contact lens (n = 15), amniotic membrane transplantation (n = 6), and tarsorrhaphy (n = 8). Complications included delayed epithelialization (n = 4, over 12 weeks), glaucoma (n = 11), and severe allograft opacity (n = 4). Only one graft rejection was observed. Conclusions Keratoplasty and KLAL can remarkably enhance VA and improve low vision or even eliminate blindness for ocular complications of SJS. The outcome of the surgeries was correlated with the preoperative ocular situation and choice of operative methods.
- Published
- 2024
- Full Text
- View/download PDF
32. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy
- Author
-
Lin M, Gong T, Ruan S, Lv X, Chen R, Su X, Cheng B, and Ji C
- Subjects
anti-tnf-α ,adalimumab ,treatment ,stevens-johnson syndrome ,toxic epidermal necrolysis ,Pathology ,RB1-214 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Min Lin,1,* Ting Gong,2,* Shifan Ruan,1,* Xiaoqing Lv,1 Rongying Chen,1 Xinhong Su,1 Bo Cheng,1 Chao Ji1 1Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350000, People’s Republic of China; 2Department of Central Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Bo Cheng; Chao Ji, Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Taijiang District, Fuzhou, 350000, People’s Republic of China, Tel +86 13859024296 ; +86 18651619908, Email bochengg@163.com; jichaofy@fjmu.edu.cnObjective: Anticancer drugs have revolutionized tumor therapy, with cutaneous toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) being common immune-related adverse events. The debate over the efficacy of systemic corticosteroids in treating these conditions persists, while tumor necrosis factor (TNF)-alpha inhibitors show promise. This study aims to evaluate the effectiveness and safety of combination therapy involving the TNF-α inhibitor adalimumab for SJS/TEN induced by anticancer drugs.Methods: A literature review of SJS/TEN cases induced by anticancer drugs from 1992 to 2023 was conducted, alongside an analysis of patients admitted to the First Affiliated Hospital of Fujian Medical University during the same period. Clinical characteristics, skin healing time, mortality, and adverse events were evaluated in two treatment groups: SJS/TEN patients treated with targeted anticancer therapies and immunotherapies.Results: Among the 27 patients studied (18 with SJS or SJS-TEN overlapping and 9 with TEN), combination therapy with adalimumab significantly reduced mucocutaneous reepithelization time and healing duration compared to corticosteroid monotherapy. Patients receiving adalimumab combined with corticosteroids had lower actual mortality rates than those on corticosteroid monotherapy. The combination therapy also showed a trend towards reducing standardized mortality rates based on the Score of Toxic Epidermal Necrolysis (SCORTEN).Conclusion: The findings suggest that adalimumab in combination with corticosteroids provides significant clinical benefits and is safer than corticosteroids alone for treating SJS/TEN induced by targeted anticancer therapies and immunotherapies. This study contributes valuable insights into potential treatment strategies for severe cutaneous adverse reactions to anticancer drugs, highlighting the importance of exploring alternative therapies such as TNF-α inhibitors in managing these conditions effectively.Keywords: anti-TNF-α, adalimumab, treatment, Stevens-Johnson syndrome, toxic epidermal necrolysis
- Published
- 2024
33. CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events.
- Author
-
Zhu, Guannan, Shi, Qiong, Cai, Tao, Gu, Dongcheng, Zhou, Hang, Wang, Lu, Liu, Fang, Wang, Ping, Xiong, Jianxia, Huang, Yujing, Li, Chunying, and Gao, Tianwen
- Subjects
TUMOR treatment ,SKIN disease treatment ,ANTIBIOTICS ,HEMORRHAGE risk factors ,BURNS & scalds -- Risk factors ,STEROID drugs ,LYMPHEDEMA treatment ,SCLERODERMA (Disease) treatment ,INFECTION risk factors ,HOLISTIC medicine ,MEDICAL protocols ,RISK assessment ,HAND-foot syndrome ,VASCULITIS ,ANTI-inflammatory agents ,CHINESE medicine ,WOUND healing ,SOFT tissue infections ,SKIN diseases ,STEVENS-Johnson Syndrome ,PSORIASIS ,ACNEIFORM eruptions ,SKIN tumors ,EXTRAVASATION ,SKIN inflammation ,ULCERS ,MICROSURGERY ,SARCOMA ,ABLATION techniques ,ERYTHEMA ,PHOTOSENSITIVITY disorders ,PROFESSIONAL associations ,MUCOUS membranes ,ENZYME inhibitors ,BALDNESS ,CHEMOEMBOLIZATION ,VITILIGO ,SEVERITY of illness index ,PHARMACEUTICAL gels ,PIGMENTATION disorders ,CHEMORADIOTHERAPY ,HEMATOMA ,SCARS ,FEVER ,CRYOSURGERY ,PHOTOTHERAPY ,ITCHING ,ANALGESICS ,LASER therapy ,MONOCLONAL antibodies ,IMMUNE checkpoint inhibitors ,OPERATIVE surgery ,METASTASIS ,INJECTIONS ,QUALITY of life ,GROWTH factors ,PAIN ,MEDICAL screening ,DRUG eruptions ,KERATOSIS ,RADIODERMATITIS ,IMATINIB ,PHOTODYNAMIC therapy ,GLUCOCORTICOIDS ,SECONDARY primary cancer ,PREVENTIVE health services ,DIET therapy ,CLASSIFICATION ,DISEASE risk factors ,DISEASE complications - Abstract
Purpose: The skin and mucous membrane of cancer patients can be directly or indirectly impaired during the treatment of cancers, bringing about not physical but also psychological damages to cancer patients. A practical guideline is of great significance to improve the quality of life for patients suffered from cutaneous adverse events. Methods: This guideline was generated based on up-to-date evidence and the consensus of experts specialized in dermatology. Results: The current guideline include the baseline screening of skin and mucosal membranes, the manifestations of injuries on skin, mucosa and appendages, along with the treatment of them. The causal anti-tumor management include chemotherapy, radiotherapy, immune therapy and surgery. Conclusion: This guideline can be helpful to reduce the risk of cutaneous adverse events during anti-cancer treatment and improve the quality of life of patients suffered from these adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Child With Stevens-Johnson Syndrome Associated With PCR-Confirmed Adenovirus Infection.
- Author
-
Mentesidou, Lida, Bachou, Theodora, Koidou, Afroditi, Zarafonitis, Georgios, Delis, Dimitrios, and Mavrikou, Mersyni
- Subjects
- *
STEVENS-Johnson Syndrome , *ADENOVIRUSES , *POLYMERASE chain reaction , *EXANTHEMA , *FEVER , *VIRUS diseases - Abstract
The article focuses on Stevens-Johnson Syndrome (SJS), a rare and life-threatening condition characterized by extensive epidermal necrosis and detachment with mucocutaneous involvement. It highlights its annual incidence, common associated drugs like anticonvulsants and NSAIDs, and the emergence of Mycoplasma-induced SJS as a distinct entity.
- Published
- 2024
- Full Text
- View/download PDF
35. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Analysis of the Russian Database of Spontaneous Reports.
- Author
-
Zyryanov, Sergey, Asetskaya, Irina, Butranova, Olga, Terekhina, Elizaveta, Polivanov, Vitaly, Yudin, Alexander, and Samsonova, Kristina
- Subjects
- *
TOXIC epidermal necrolysis , *DRUG side effects , *STEVENS-Johnson Syndrome , *AZITHROMYCIN , *DOPING in sports , *DATABASES , *CARBAMAZEPINE , *VALPROIC acid , *LACTAMS - Abstract
(1) Background: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are extremely severe cutaneous adverse drug reactions which are relatively rare in routine clinical practice. An analysis of a national pharmacovigilance database may be the most effective method of obtaining information on SJS and TEN. (2) Methods: Design—a retrospective descriptive pharmacoepidemiologic study of spontaneous reports (SRs) with data on SJS and TEN retrieved from the Russian National Pharmacovigilance database for the period from 1 April 2019 to 31 December 2023. Descriptive statistics was used to assess the demographic data of patients and the structure of suspected drugs. (3) Results: A total of 170 SRs on SJS and TEN were identified, of which 32.9% were SJS and 67.1%—TEN. In total, 30% were pediatric SRs, 21.2%—SRs of the elderly. There were 12 lethal cases, and all cases were TEN. The leading culprit drugs were anti-infectives for systemic use and nervous system agents. The top 10 involved drugs are as follows: lamotrigine (23.5%), ibuprofen (12.9%), ceftriaxone (8.8%), amoxicillin and amoxicillin with beta-lactam inhibitors (8.8%), paracetamol (7.6%), carbamazepine (5.9%), azithromycin (4.1%), valproic acid (4.1%), omeprazole (3.5%), and levetiracetam (3.5%). (4) Conclusions: Our study was the first study in Russia aimed at the assessment of the structure of the drugs involved in SJS and TEN on the national level. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients.
- Author
-
Erduran, Funda, Adışen, Esra, Emre, Selma, Hayran, Yıldız, Başkan, Emel Bülbül, Yazıcı, Serkan, Bilgiç, Aslı, Alpsoy, Erkan, Günaydın, Sibel Doğan, Elmas, Leyla, Akyol, Melih, Güner, RukiyeYasak, Arıca, Deniz Aksu, Aypek, Yağmur, Ergun, Tülin, Karavelioğlu, Dilan, Yazıcı, Ayça Cordan, Aydoğan, Kübra, Bayramgürler, Dilek, and Kıran, Rebiay
- Subjects
- *
TOXIC epidermal necrolysis , *STEVENS-Johnson Syndrome , *MORTALITY , *NOSOLOGY , *REGRESSION analysis , *ODDS ratio - Abstract
Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening acute mucocutaneous disorders usually triggered by drugs. In this study, we aimed to evaluate the factors affecting mortality in patients with SJS-TEN. Methods: Our study is a retrospective cohort study, analyzing data collected from a total of 12 tertiary care centers between April 2012 and April 2022. Results: The study included 59 males and 107 females, a total of 166 patients, with an average age of 50.91 ± 21.25 years. Disease classification was TEN in 50% of cases, SJS in 33.1%, and SJS-TEN overlap in 16.9%. The average SCORTEN within the first 24 h was 2.44 ± 1.42. Supportive care was provided to 99.4% of patients. The most commonly used systemic immunomodulatory treatments were systemic steroids (84.3%), IVIG (intravenous immunoglobulin) (49.3%), and cyclosporine (38.6%). Plasmapheresis was administered to five patients. While 66.3% of patients were discharged, 24.1% resulted in exitus. Our comparative analysis of survivors and deceased patients found no effect of systemic steroids, IVIG, and cyclosporine treatments on mortality. Univariate analysis revealed that the SCORTEN scores on days 1 and 3 as well as the rates of detachment at the onset and during follow-up were significantly higher in deceased patients compared to survivors. The rates of fever, positive blood cultures, and systemic antibiotic use were higher in deceased patients compared to survivors. The presence of comorbidities, diabetes, and malignancy were significantly more common in deceased patients. Multivariate regression analysis indicated that over SCORTEN 2, the mortality risk exponentially rose with each SCORTEN increment, culminating in an 84-fold increase in mortality at SCORTEN 5–6 (odds ratio [95% confidence interval]: 13.902–507.537, p < 0.001) compared to SCORTEN 0–1. Additionally, the utilization of plasmapheresis was associated with a 22-fold increase in mortality (odds ratio [95% confidence interval]: 1.96–247.2, p = 0.012). Conclusion: Our study found that a high SCORTEN score within the first 24 h and the use of plasmapheresis were related to increased mortality, while systemic steroids, IVIG, and cyclosporine treatments had no impact on mortality. We believe that data gathered from one of the most comprehensive studies which we conducted on SJS-TEN will enrich the literature, although additional research is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Antibiotic-associated vanishing bile duct syndrome: a real-world retrospective and pharmacovigilance database analysis.
- Author
-
Wang, Jianglin, Wang, Shengfeng, Wu, Cuifang, and Deng, Zhenzhen
- Subjects
ANTIBIOTICS ,RISK assessment ,PHARMACOLOGY ,CARBAPENEMS ,FLUOROQUINOLONES ,TETRACYCLINE ,STEVENS-Johnson Syndrome ,PATIENT safety ,BETA lactam antibiotics ,EXANTHEMA ,FATIGUE (Physiology) ,ASTHENIA ,TOXIC epidermal necrolysis ,BILE duct diseases ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,BILIRUBIN ,CO-trimoxazole ,CONFIDENCE intervals ,MACROLIDE antibiotics ,LIVER function tests ,DISEASE risk factors ,SYMPTOMS - Abstract
Purpose: Vanishing bile duct syndrome (VBDS) is a rare, but potentially fatal adverse reaction triggered by certain medications. Few real-world studies have shown association between antibiotics and VBDS. We sought to quantify the risk and evaluate the clinical features of VBDS associated with antibiotics. Methods: Data from 2004 to 2022 on VBDS events induced by antibiotics were retrieved from the FDA Adverse Event Reporting System (FAERS) database and disproportionality analyses were conducted. Furthermore, case reports from 2000 to 31 December 2022 on antibiotics-induced VBDS were retrieved for retrospective analysis. Results: We collected 132 VBDS reports from the FAERS database. Fluoroquinolones had the greatest proportion and highest positive signal values of VBDS. The RORs (95% CIs) for antibiotics were fluoroquinolones 23.68 (18.12–30.95), macrolides 19.37 (13.58–27.62), carbapenems 17.39 (7.77–38.96), beta-lactam 13.28 (9.69–18.20), trimethoprim/sulfamethoxazole 9.05 (5.57–14.7), and tetracycline 4.02 (1.50–10.77). Twenty-three cases from 22 studies showed evidence of VBDS, beta-lactam (52.2%) was the most frequently reported agent. The median age was 45 years, the typical initial symptoms included rash (30.4%), fatigue/asthenia (26.1%), dark urine (21.7%) and Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) (21.7%). The median time to onset of VBDS was 2 weeks. All cases had abnormal liver function test, and the median level of total bilirubin was 23.6 mg/dl (range 3.2–80 mg/dl). Cessation of culprit drugs and treatment with ursodeoxycholic acid (83.3%) were not associated with improved outcomes (57.1%). Conclusion: This study identified thirteen antibacterial agents with significant reporting associations with VBDS. Fluoroquinolones may be a neglected agent of inducing VBDS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Empowering advanced clinical practitioners in managing acute dermatological emergencies.
- Author
-
Hazim Alsararatee, Hasan
- Subjects
- *
SKIN disease treatment , *VASCULITIS , *PHYSICAL diagnosis , *BLISTERS , *SELF-efficacy , *ACUTE diseases , *STEVENS-Johnson Syndrome , *EXFOLIATIVE dermatitis , *HOSPITAL care , *DISEASE management , *DERMATOLOGY , *TOXIC epidermal necrolysis , *EXANTHEMA , *PURPURA (Pathology) , *DRESS syndrome , *PEMPHIGUS , *DECISION making in clinical medicine , *NURSE practitioners , *HOSPITAL medical staff , *KAPOSI varicelliform eruption , *NECROTIZING fasciitis , *EMERGENCY nursing , *CLINICAL competence - Abstract
Advanced clinical practitioners (ACPs) encounter patients with acute dermatological presentations ranging from minor to life-threatening conditions in both primary and secondary care settings. However, ACPs often feel unprepared to assess and treat patients with dermatological emergencies. This article aims to provide guidance to trainee and qualified ACPs, whether in acute hospital settings or primary care, in understanding the essential aspects to consider when consulting with patients presenting with acute dermatological emergencies. It also emphasises appropriate referrals to relevant specialties for necessary inpatient or outpatient investigations and ensure prompt treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Trichiasis in cicatricial ocular surface disease: a multi-center comparison of electroepilation versus eyelash resection outcomes.
- Author
-
Sinha, Prerna, Nagano, Hiromi, Watanabe, Akihide, and Singh, Swati
- Abstract
PurposeMethodsResultsConclusionTo evaluate the outcomes of trichiasis (excluding entropion) management in non-trachomatous cicatricial ocular surface diseases.This is a multicenter, retrospective study of 59 patients with trichiasis who were managed using two different techniques: electroepilation using radiofrequency (RF) cautery and eyelash resection. The assessed outcomes were residual trichiasis at 6 weeks, 6, and 12 months of follow-up and the number of procedures needed.41 patients (90 eyelids) underwent electroepilation, and 18 (41 eyelids) were managed with eyelash resection. All patients belonged to either Indian or Japanese ethnicity. Most patients in both groups had Stevens-Johnson Syndrome (63.4% vs. 88.9%). The mean age (43.2 vs. 46 years), disease duration (122 vs. 192.4 months), median trichiasis grade (2 vs. 2), and involvement of upper eyelids (53/90 vs. 23/41) were similar in the two groups. At six weeks, 48.9% of eyelids that underwent electroepilation had no trichiasis, and recurrences were managed with repeat electroepilation (6 eyelids) and mucous membrane grafting (10 eyelids), and 35 eyelids opted for manual epilation, giving 67.8% success at a mean follow-up of 20 months. The eyelash resection group had 75.6% success at 6 months, and recurrences were managed using lid splitting and eyelash resection, resulting in 100% success at a mean follow-up of 79 months. More interventions were needed in the electroepilation group compared to eyelash resection.Eyelash resection of the trichiatic eyelashes achieves a better success rate than electroepilation in cicatricial ocular surface disorders. Following electroepilation, one needs multiple interventions to resolve trichiasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Absence of Epidermal Antibodies in Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Patients but Beware of Single Positive Results.
- Author
-
Diercks, Gilles F. H., Meijer, Joost M., Bolling, Maria C., Scholtens-Jaegers, Sonja M. H. J., Bremer, Jeroen, and Horvath, Barbara
- Subjects
- *
PROTEINS , *STEVENS-Johnson Syndrome , *TOXIC epidermal necrolysis , *IMMUNOGLOBULINS , *ENZYME-linked immunosorbent assay , *FLUORESCENT antibody technique , *PEMPHIGUS , *KERATINOCYTES , *RATS , *ANIMAL experimentation , *AUTOIMMUNE diseases , *SERODIAGNOSIS , *IMMUNOBLOTTING , *PRECIPITIN tests , *PRIMATES - Abstract
Background. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare and potentially life-threatening mucocutaneous blistering diseases that clinically can resemble autoimmune bullous diseases. Moreover, it has been shown that autoantibodies against epidermal proteins are present in SJS/TEN. Objectives. To establish the presence of antibodies against desmosomal and hemidesmosomal proteins in confirmed SJS/TEN patients. Methods. Serum of SJS/TEN patients diagnosed based on clinical criteria, e.g., epidermal detachment with erosions and severe mucosal lesions, (suspicion of) a culprit drug, and matching histologic results was evaluated by various techniques, e.g., indirect immunofluorescence on monkey esophagus, salt split skin and rat bladder, immunoblotting (IB) and immunoprecipitation (IP), ELISAs against desmogleins and BP180, keratinocyte footprint assay, and keratinocyte binding assay. Results. A total of 28 patients were included in this study, 15 men and 13 women with a mean age of 56 years. In most patients, none of the serological tests were positive. In two patients, an elevated DSG3 titer was found suspicious for pemphigus vulgaris. Three patients had elevated NC16a titers, suggesting bullous pemphigoid. However, in all these patients, no other tests were positive and in these patients, the biopsy for direct immunofluorescence showed no evidence for an autoimmune bullous disease. Three patients showed reactivity against rat bladder rat bladder; these were, however, completely negative for A2ML1, envoplakin, and periplakin in the IB as well as the IP. Conclusions. Serological analysis for desmosomal and hemidesmosomal antibodies is reliable to rule an autoimmune bullous disease in patients with suspected SJS/TEN. However, one should not rely on one single test method since false positive results can occur. Moreover, this study also makes it less plausible that antibodies against desmosomal and/or hemidesmosomal components are involved in the pathogenesis of SJS/TEN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. The outcomes of corneal sight rehabilitating surgery in Stevens-Johnson syndrome: case series.
- Author
-
Peng, Rongmei, Chi, Miaomiao, Xiao, Gege, Qu, Hongqiang, Shen, Zhan, Zhao, Yinghan, and Hong, Jing
- Subjects
STEVENS-Johnson Syndrome ,CORNEA ,LOW vision ,CORNEAL transplantation ,AMNION ,SURGICAL complications - Abstract
Purpose: To summarize the outcomes of corneal sight rehabilitating surgery in Stevens-Johnson syndrome (SJS). Methods: This is a retrospective analysis of a consecutive case series. Twenty-four eyes of 18 SJS patients were included in this study. The ocular parameters, surgical procedures, postoperative complications, and additional treatments of the cases were reviewed. Results: A total of 29 corneal sight rehabilitating surgeries, which consists of 9 keratoplasties, 8 Keratolimbal allograft (KLAL) and 12 combined surgeries (keratoplasty and KLAL simultaneously) were performed on the 24 eyes. All patients were treated with glucocorticoid eyedrops and tacrolimus eyedrops for anti-rejection treatment without combining systemic immunosuppression, except two patients who were prescribed prednisone tablets for the management of systemic conditions. The mean follow-up period was 50.6 ± 28.1 months. The optimal visual acuity (VA) (0.74 ± 0.60 logarithm of the minimum angle of resolution [logMAR]) and endpoint VA (1.06 ± 0.82 logMAR) were both significantly better than the preoperative VA (1.96 ± 0.43 logMAR) (95% CI, p = 0.000). 57.1% patients (8/14) were no longer in the low vision spectrum, and 88.9% patients (8/9) were no longer blind. The mean epithelialization time was 7.1 ± 7.6 weeks. The success rate was 86.7%. Additional treatments for improving epithelialization included administration of serum eyedrops (n = 10), contact lens (n = 15), amniotic membrane transplantation (n = 6), and tarsorrhaphy (n = 8). Complications included delayed epithelialization (n = 4, over 12 weeks), glaucoma (n = 11), and severe allograft opacity (n = 4). Only one graft rejection was observed. Conclusions: Keratoplasty and KLAL can remarkably enhance VA and improve low vision or even eliminate blindness for ocular complications of SJS. The outcome of the surgeries was correlated with the preoperative ocular situation and choice of operative methods. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System.
- Author
-
Godfrey, Hannah, Jedlowski, Patrick, and Thiede, Rebecca
- Subjects
- *
IMMUNE checkpoint inhibitors , *FOOD chemistry , *TOXIC epidermal necrolysis , *DRUG eruptions , *ANTINEOPLASTIC agents , *IPILIMUMAB , *STEVENS-Johnson Syndrome - Abstract
Background/Objectives: The immune checkpoint inhibitors (ICIs) have been increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions, including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are uncommon but potentially lethal. Despite the severity of these reactions and growing association with the ICIs, their specific risk and mortality rates have been largely unexplored. Methods: A case/non‐case analysis was performed using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to examine the reporting odds ratios (RORs) for ICI‐associated SCARs cases under two conditions: (1) ICIs compared with all drugs in FAERS and (2) ICIs compared with a reference group of pooled anticancer drugs to control for underlying malignancy. Results: A statistically significant ROR for SJS (ROR: 5.44), TEN (ROR: 5.81) and DRESS (ROR: 1.38) were identified under Condition 1. Under Condition 2, this significance was maintained for SJS (ROR: 7.31), TEN (ROR: 7.40) and DRESS (ROR: 3.90), and mild significance was identified for AGEP (ROR: 1.89). Mortality rates for the ICIs were increased compared with the anticancer medications (28.5% vs. 24.5% for SJS, 55.3% vs. 46% for TEN, 3.0% vs. 2.1% for AGEP and 7.1% vs. 6.1% for DRESS). Conclusions: Our results suggest an association between SCARs and the ICIs independent of cancer status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Visual outcome and postoperative complications of cataract surgery in patients with ocular surface disorders.
- Author
-
Aggarwal, Manvi, Gour, Abha, Gupta, Nidhi, Singh, Aastha, and Sangwan, Virender
- Subjects
- *
CATARACT surgery , *SURGICAL complications , *PHACOEMULSIFICATION , *ALLERGIC conjunctivitis , *DRY eye syndromes , *STEVENS-Johnson Syndrome - Abstract
Purpose: To determine the visual outcome and postoperative complications of cataract surgery in patients with ocular surface disorders (OSDs). Setting: Tertiary eyecare center in North India. Design: Retrospective observational study. Methods: Patients with various OSDs with stabilized ocular surfaces who underwent cataract surgery during this period and had a minimum postoperative follow-up of 6 weeks were included. The primary outcome measures were postoperative corrected distance visual acuity (CDVA) at 6 weeks, best CDVA achieved, and post-operative complications. Results: The study included 20 men and 24 women. A total of 55 eyes were evaluated: Stevens-Johnson syndrome (SJS) 35 eyes, ocular cicatricial pemphigoid (OCP) 4 eyes, 8 eyes with dry eye disease (DED), 6 eyes with chemical injury and 2 eyes with vernal keratoconjunctivitis (VKC). The mean duration of OSD was 33.9 ± 52.17 months. The median preoperative CDVA was 2.0 (interquartile range [IQR], 1.45 to 2.0). The median CDVA ever achieved was 0.50 (IQR, 0.18 to 1.45) at 2 months and the median CDVA at 6 weeks was 0.6 (IQR, 0.3 to 1.5). Maximum improvement in CDVA was noted in patients with DED and SJS and the least in OCP. Phacoemulsification was performed in 47.27% eyes with intraoperative complications noted in 9% eyes. Postoperative surface complications occurred in 12 (21.82%) eyes. Other postoperative complications occurred in 9 (16%) eyes. Conclusions: Cataract surgery outcome can be visually rewarding in patients with OSDs provided ocular surface integrity is adequately maintained preoperatively and postoperatively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Fever with Rash in a Child: Revisited.
- Author
-
Sarkar, Rashmi, Yadav, Anukriti, and Maheshwari, Apoorva
- Subjects
- *
DIFFERENTIAL diagnosis , *EARLY medical intervention , *STAPHYLOCOCCAL diseases , *STEVENS-Johnson Syndrome , *EXANTHEMA , *MEASLES , *TOXIC epidermal necrolysis , *SCARLATINA , *SCHOENLEIN-Henoch purpura , *EPSTEIN-Barr virus diseases , *FEVER , *DENGUE , *DRESS syndrome , *SYSTEMIC lupus erythematosus , *CHIKUNGUNYA , *RUBELLA , *RICKETTSIAL diseases , *TOXIC shock syndrome , *CHICKENPOX , *MONKEYPOX , *JOINT pain , *DRUG eruptions , *ACRODERMATITIS , *MUCOCUTANEOUS lymph node syndrome , *PARVOVIRUS diseases , *HAND, foot & mouth disease , *COVID-19 , *TYPHOID fever , *CHILDREN - Abstract
Rash and fever are some of the most common chief complaints present in paediatric dermatology emergencies. The spectrum of differential diagnosis is broad, including many different infectious and some non-infectious agents. A systematic approach involving detailed history taking, careful clinical examination along with particular attention to epidemiological features are the most important factors to make a diagnosis. This article reviews the morphological patterns of various causes of fever with rash in children, including infectious as well as non-infectious causes, with special emphasis on the Indian scenario. We intend to highlight the clinical characteristics of each cause, which will not only help make a clinical diagnosis but also distinguish benign versus life-threatening causes of skin rash in febrile paediatric patients and provide early medical intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Farmacodermias: ¿cuántas y cuáles?
- Author
-
Villeda Aguilar, María de los Ángeles, Rafael Pineda, Marla Gladys, Alberti Minutti, Paolo, Lazcano Prieto, Bonfilio Roberto, and Sevilla Santoyo, Mizael Orlando
- Abstract
OBJECTIVES: To determine the frequency of pharmacodermias in the Hospital Ángeles Metropolitano, Mexico City, as well as to examine the clinical characteristics and etiological agents. MATERIALS AND METHODS: An observational, descriptive, cross-sectional and retrospective study was carried out from March 2022 to June 2023. Patients hospitalized at the Hospital Ángeles Metropolitano, Mexico City, over 18 years of age, with a diagnosis of mucocutaneous adverse drug reactions were included. RESULTS: Of the 16,651 hospitalized patients in the period of study, 104 were selected for diagnosis of mucocutaneous adverse drug reaction. The prevalence was of 6.24/1000 hospitalized patients, with a predominance of female sex (62.5%). The most frequent pharmacodermia was maculopapular exanthema, followed by urticaria with or without angioedema. Serious adverse drug reactions, such as Stevens-Johnson syndrome, accounted for 1%. The most related drugs were antibiotics, followed by nonsteroidal anti-inflammatory drugs. CONCLUSIONS: The results of this study agree with those reported in the national and international literature; however, epidemiological studies on pharmacodermias in Mexico should be continued in order to establish a more realistic national incidence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Prevalencia y caracterización de las reacciones cutáneas graves por medicamentos en pacientes hospitalizados en dos centros hospitalarios de Bogotá, 2010-2020.
- Author
-
Tamara Gutiérrez, María Paula, Torres Pradilla, Mauricio, Maya Gómez, Mónica, Herazo Aguirre, Isabel, and Toscano Madero, María Camila
- Abstract
OBJECTIVE: To determine the prevalence of severe cutaneous adverse reactions to medications in hospitalized patients of two hospitals of Bogota, Colombia. MATERIALS AND METHODS: An exploratory cross-sectional observational study conducted in two hospitals in Bogota, Colombia, from 2010 to 2020 of patients diagnosed with severe cutaneous adverse reactions to medications collected by reviewing medical records. RESULTS: A total of 42 cases were found with a mean age of 40.8 years and a male predominance. The acute generalized exanthematous pustulosis was the most frequently reported reaction in 15 patients, followed by drug-induced hypersensitivity syndrome (DRESS syndrome): 11, Stevens-Johnson syndrome: 7, toxic epidermal necrolysis: 5 and generalized bullous fixed pigmented erythema: 4. The main triggering drugs were antibiotics in 19 cases and anticonvulsants in 9. Systemic corticosteroids were the main treatment received by 26 patients. Three patients died. CONCLUSIONS: Future pharmacogenetic studies are needed to determine susceptibility to different drugs in the Colombian population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Clinical Characteristics and Treatment of Ophthalmic Sequelae of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis at a Tertiary Eyecare Centre in Hungary.
- Author
-
Tóth, Gábor, Lukács, Andrea, Stachon, Tanja, Schirra, Frank, Sándor, Gábor László, Nagy, Zoltán Zsolt, and Szentmáry, Nóra
- Subjects
- *
TOXIC epidermal necrolysis , *STEVENS-Johnson Syndrome , *AMNION , *ANTICONVULSANTS , *DISEASE complications , *CATARACT surgery - Abstract
Introduction: This study analysed the causative factors and clinical characteristics of acute and chronic ocular sequelae of Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) treated at a large third-referral centre in a developed country (Hungary) over a 15-year period. Methods: This was a retrospective review of patients with acute and/or chronic SJS/TEN who were managed between 2006 and 2020 at the Department of Ophthalmology of Semmelweis University in Budapest, Hungary. For each subject, clinical data, including patient demographics, clinical history, causative agents of SJS/TEN, and conservative and surgical treatment details, were reviewed. Results: Ninety-six eyes of 48 patients were included (28 female; 58.3%); the age at disease onset was 32.1 ± 22.4 years. The most common causative factors were medicines (n = 36; 75.0%). Among these drugs, 29.2% were nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 14), 20.8% were antibiotics (n = 10) and 14.6% were antiepileptic drugs (n = 7). In patients with chronic SJS/TEN, the most commonly found ocular sequelae were conjunctival hyperaemia in 45 (56.3%) eyes, symblepharon in 38 (47.5%) eyes, trichiasis/distichiasis in 37 (46.3%) eyes, corneal neovascularization in 31 (38.8%) eyes and corneal scarring in 29 (36.3%) eyes. In patients with chronic SJS/TEN, the most frequently used topical conservative treatment included antibiotics in 53 (66.3%) eyes, preservative-free artificial tears in 50 (62.5%) eyes and topical corticosteroids in 42 (52.5%) eyes of 40 patients. The most frequently performed ocular surgeries for managing chronic ocular sequelae in patients with SJS/TEN were epilation for trichiasis (n = 27; 33.8%), cataract surgery (n = 14; 17.5%), entropion surgery (n = 12; 15.0%), penetrating keratoplasty (PK) (n = 11; 13.8%) and amniotic membrane transplantation (n = 4; 5.0%). Conclusion: Our results suggest that NSAIDs, antibiotics and antiepileptic drugs are the most common causative factors for SJS/TEN in Hungary. Like in other countries, in Hungary, the ocular management of patients with acute and chronic SJS/TEN is heterogeneous, and most cases do not follow modern therapeutic guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Single‐dose ibuprofen induced Stevens–Johnson Syndrome.
- Author
-
Alhatemi, Ahmed Qasim Mohammed, Hashim, Hashim Talib, Al‐Tarbosh, Muhamad Abdulrahman Shyea, Abdulhussain, Rand, and Hashim, Ali Talib
- Subjects
- *
STEVENS-Johnson Syndrome , *DRUG side effects , *MEDICAL personnel , *IBUPROFEN , *PATIENT education , *PATIENT safety - Abstract
Key Clinical Message: Ibuprofen single dose may rarely induce Stevens–Johnson Syndrome, emphasizing the vital need for heightened vigilance in healthcare and public awareness for safer medication practices. Stevens–Johnson Syndrome (SJS) is a severe and potentially life‐threatening skin disorder associated with certain medications, including ibuprofen. We present a case of a 45‐year‐old woman who developed SJS following a single dose of ibuprofen. Despite its rarity, this case underscores the importance of heightened vigilance in healthcare and public awareness regarding the potential risks of commonly used medications. Prompt recognition of SJS symptoms and immediate medical intervention are crucial for patient outcomes. Healthcare providers should exercise caution when prescribing ibuprofen, particularly in patients with a history of adverse drug reactions. This case emphasizes the need for ongoing monitoring, patient education, and informed decision‐making to promote medication safety and optimal patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. SINDROM STEVENS JOHNSON PADA PASIEN DENGAN HIV REAKTIF.
- Author
-
Novriana, Dita Eka and Mochtar, Moerbono
- Subjects
- *
STEVENS-Johnson Syndrome , *TOXIC epidermal necrolysis , *ALLERGIES , *HIV , *ANTIRETROVIRAL agents - Abstract
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are acute druginduced hypersensitivity reactions that can be life-threatening. HIV/AIDS infection is a predisposing factor for SJS and TEN. The management of SJS and TEN is supportive and symptomatic. This study aims to provide an overview of the management of SJS and TEN in a patient with HIV/AIDS. The research method used a case study of a 29-year-old woman with HIV/AIDS who experienced SJS and TEN after taking antiretroviral drugs (ARVs). The patient had been diagnosed with HIV and had been taking ARVs, including nevirapine, lamivudine, and zidovudine, since October 2019. Physical examination revealed ruptured bullae, hemorrhagic crusts, erosions, and epidermal detachment. The patient's management included intravenous methylprednisolone 62.5mg/24 hours tapered off, compression with 0.9% NaCl for 10-15 minutes followed by application of 0.1% triamcinolone acetonide ointment twice daily on oral erosions, and gentamicin ointment twice daily on body erosions. SJS and TEN are characterized by purpuric macules, bullae, atypical target lesions, and epidermal detachment. Nevirapine is a known culprit drug for SJS and TEN in patients with HIV/AIDS. Patients with HIV/AIDS are at higher risk of developing SJS and TEN. Systemic corticosteroids, intravenous immunoglobulins, and other immunosuppressive therapies can be used for these cases. Stevens-Johnson Syndrome is a drug-induced hypersensitivity reaction that often occurs in HIV/AIDS infection. This condition can be caused by ARVs such as nevirapine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Antiepileptic Medication-induced Severe Cutaneous Adverse Reactions in Hospitalized Children: A Retrospective Study.
- Author
-
Abtahi-Naeini, Bahareh, Makhmali, Reza, Amini, Niloufar, Maracy, Mohammad Reza, Nouri, Nikta, and Momen, Tooba
- Subjects
- *
HOSPITAL care of children , *IRANIANS , *ANTICONVULSANTS , *DRUG side effects , *RETROSPECTIVE studies , *STEVENS-Johnson Syndrome - Abstract
There are limited data on severe cutaneous adverse reactions (SCARs) associated with antiepileptic medications. The current study aims to investigate the clinical and epidemiological characteristics of antiepileptic medication-induced SCARs in hospitalized children. This five-year retrospective study was conducted at Isfahan University of Medical Sciences, Iran. The study included all children with a diagnosis of SCARs secondary to antiepileptic medications as defined by the World Health Organization (WHO). In our study SCARs were categorized into three groups: drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and a group with symptoms overlapping between maculopapular eruptions (MPE) and DRESS. Among 259 children with SCARs induced by antiepileptic medications, 199 (76.83%), 42 (16.22%), and 18 (6.95%) had overlapping MPE/DRESS, DRESS, and SJS/TEN, respectively. Phenobarbital was the most common offending drug among SCARs. The multinomial logistic regression model revealed that lymphadenopathy increased DRESS occurrence by 35 times compared to overlapping MPE/DRESS. Girls were at risk of SJS/TEN approximately 6 times more than boys. Age, weight, and mucosal involvement affected hospitalization duration in children with SCARs related to antiepileptic medication. There are some similarities and differences in the clinical and epidemiological features of Iranian children suffering from antiepileptic medication-induced SCARs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.